Peptide receptor radionuclide therapy with (90)Y-DOTATATE/(90)Y-DOTATOC in patients with progressive metastatic neuroendocrine tumours: assessment of response, survival and toxicity

BACKGROUND: Peptide receptor radionuclide therapy (PRRT) is an established treatment for patients with metastatic neuroendocrine tumours (NETs), although which factors are associated with an improved overall survival (OS) remains unclear. The primary aim of this study is to determine to what extent...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Vinjamuri, S, Gilbert, T M, Banks, M, McKane, G, Maltby, P, Poston, G, Weissman, H, Palmer, D H, Vora, J, Pritchard, D M, Cuthbertson, D J
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2013
Assuntos:
Translational Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3629418/
https://ncbi.nlm.nih.gov/pubmed/23492685
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2013.103
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
A carregar...

Registos relacionados